A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Dactolisib (Primary) ; Abiraterone acetate; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.